The earnings call highlighted significant strategic moves, such as the sale of the oncology business and FDA approval for the 4Kscore test, indicating strong steps towards future profitability. However, these positives are tempered by ongoing revenue challenges in the Diagnostics segment and increased operating losses in the Pharmaceutical segment, as well as the slower-than-expected adoption of key products.

Company Guidance -

Q3 2025

During OPKO Health's second quarter 2025 financial results call, the company provided several key metrics and updates. They reported $101.1 million in revenue from their Diagnostics business, including $24.9 million from oncology assets being sold, and a total operating loss of $18.2 million. The Pharmaceutical business saw revenue of $55.7 million, with product revenue at $40.7 million and IP transfer revenue at $15 million, including a $6.1 million profit share from Pfizer. The company highlighted strategic moves like the pending sale of BioReference's oncology assets for $225 million, expected to close by the end of Q3 2025. They also discussed their innovative pipeline, including ModeX's programs with two in Phase I clinical trials and three more anticipated to enter the clinic by the end of 2026. OPKO has a $200 million common stock repurchase program with $141.5 million remaining capacity. They are targeting to achieve cash flow breakeven for their Diagnostics business in 2025, excluding nonrecurring and noncash items.

BioReference Health Streamlining and Sale

OPKO Health is selling its oncology and clinical testing business to Labcorp for $225 million, with $192.5 million payable at closing. This transaction is expected to improve BioReference's financial profile and focus on core testing business.

Pharmaceutical Pipeline Progress

ModeX has 2 programs in Phase I clinical trials with 3 more expected to enter the clinic by early 2026. Phase I data from the EBV vaccine partnered with Merck is a significant catalyst for the pipeline.

4Kscore Test FDA Approval

The FDA approved a supplemental application for the 4Kscore test, allowing its performance without digital rectal examination information, potentially increasing its user base.

Diagnostics Segment Cost Savings

BioReference Health achieved annualized cost savings of approximately $19 million due to headcount reduction and footprint consolidation, with further savings expected post-oncology transaction close.

Latin American and Irish Business Performance

OPKO's Latin American and Irish units continued to perform well with increasing revenue and expanding margins despite foreign currency headwinds.

Opko Health (OPK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OPK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.08 / -	0.03	―	―	―
Jul 31, 2025	2025 (Q2)	-0.11 / -0.19	-0.01	-1800.00% (-0.18)	―
Apr 30, 2025	2025 (Q1)	-0.07 / -0.10	-0.12	16.67% (+0.02)	―
Feb 27, 2025	2024 (Q4)	-0.09 / 0.01	-0.09	111.11% (+0.10)	―
Nov 07, 2024	2024 (Q3)	-0.09 / 0.03	-0.11	127.27% (+0.14)	―
Aug 07, 2024	2024 (Q2)	-0.10 / -0.01	-0.03	66.67% (+0.02)	―
May 07, 2024	2024 (Q1)	-0.10 / -0.12	-0.02	-500.00% (-0.10)	―
Feb 27, 2024	2023 (Q4)	-0.10 / -0.09	-0.11	18.18% (+0.02)	―
Nov 06, 2023	2023 (Q3)	-0.10 / -0.11	-0.11	0.00% (0.00)	―
Aug 03, 2023	2023 (Q2)	-0.07 / -0.03	-0.14	78.57% (+0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OPK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$1.28	$1.19	-7.03%
Apr 30, 2025	$1.38	$1.35	-2.17%
Feb 27, 2025	$1.63	$1.74	+6.75%
Nov 07, 2024	$1.45	$1.52	+4.83%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Opko Health Inc (OPK) report earnings?

Opko Health Inc (OPK) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Opko Health Inc (OPK) earnings time?

Opko Health Inc (OPK) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OPK EPS forecast?

OPK EPS forecast for the fiscal quarter 2025 (Q3) is -0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing